Target Trial Emulation Applications in Hypertension Research: A scoping Review

Amir Habibdoust[1†], PhD; Hanxiao Zuo[2], MS; Aditi Gupta[3], MD, MS; Richelle J. Koopman[4], MD, MS; Diego R. Mazzotti[5], PhD; Nelson Pace[6], PhD, SM; Xing Song[7], PhD.

1. Institute for Data Science and Informatics, University of Missouri-Columbia, Missouri, USA
2. School of Public Health, University of Alberta, Edmonton, Alberta, Canada.
3. Division of Nephrology and Hypertension, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS, USA
4. Department of Family and Community Medicine, University of Missouri-Columbia, Columbia, Missouri, United States
5. Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS, USA
6. AbbVie, North Chicago, IL, USA
7. Department of Biomedical Informatics, Biostatistics, and Medical Epidemiology, University of Missouri-Columbia, Missouri, USA.

[†]Corresponding Author
Amir Habibdoust, PhD, PhD Student, Institute for Data Science and Informatics, University of Missouri-Columbia, 22 Heinkel Building. | Columbia, MO 65212, Email: ahb3b@missouri.edu, Tel: +1 (573) 864-9659

Xing Song, PhD, Assistant Professor, Department of Biomedical Informatics, Biostatistics, and Medical Epidemiology (BBME), University of Missouri-Columbia, 1 Hospital Dr. | Columbia, MO 65212, Email: xsm7f@missouri.edu, Tel: +1 (573) 882-1352

Abstract

Objectives
Target Trial Emulation (TTE) has emerged as a rigorous framework for causal inference using observational data, but its application in hypertension research remains underexplored. This scoping review aims to map current TTE applications, identify methodological strengths and weaknesses, and propose future directions in hypertension research.
Study Design and Setting
We performed a scoping review following the Joanna Briggs Institute (JBI) guidance and the PRISMA extension for Scoping Reviews (PRISMA-ScR) checklist. We searched multiple databases, and three independent reviewers conducted screening and extraction using Covidence review management software. Of 1,157 articles identified, 14 met the inclusion criteria.
Results
Most studies used data from electronic health records, claims databases, and registries. Common confounding adjustment methods included inverse probability weighting and the g-formula, complemented by regression-based models. However, time-varying confounders were inconsistently addressed, and loss to follow-up was often managed through simple censoring rather than statistical methods. Residual confounding remained a concern—although several studies acknowledged unobserved confounders, only a few employed negative controls or e-values to assess their impact. While subgroup analyses were common, explicit heterogeneous treatment effect (HTE) estimation was limited. Advanced causal machine learning techniques for bias mitigation or HTE detection were not reported.
Conclusion
TTE shows strong potential to complement randomized controlled trials in hypertension research by providing more generalizable insights. While still in its early stages, current studies highlight its ability to address key challenges such as HTE, long-term outcomes, and dynamic treatment strategies.

Key words: Target Trial Emulation, Hypertension, Observational Data, Heterogeneous Treatment Effect; Scoping Review.

1. Introduction

Hypertension is a considerable risk factor associated with a range of health issues, including cardiovascular disease, stroke, chronic kidney disease, and cognitive decline[1–3] and is a leading preventable risk factor for global mortality[4]. Despite advancements in blood pressure measurement methods and the availability of effective and safe antihypertensive medications[5], globally only 23% of treated women and 18% of treated men achieve targeted pressure levels[6]. While there has been significant progress in our understanding of blood pressure, challenges and open questions still persist in the field[7–9]: these include, but are not limited to, causes of hypertension[10], the heterogeneous effectiveness and safety of different drug classes across diverse groups (ranging from children to older adults, and across different races, sexes, and diseases)[8,11,12], blood pressure variability[13], and barriers and promoters to short-term and long-term adherence to hypertension treatment[8].

However, many questions are infeasible and impractical to be addressed with RCTs, due to high time and effort consumption, high costs, high compliance burden for participants, low tolerance of deviation from study protocol[12], and measurement error[14–16], to name a few. The constricted patient selection criteria of many RCTs and other limiting recruitment factors (e.g. geography) often lead to a significant lack of generalizability (external validity)[17–19], and missing the opportunities to consider complex heterogeneity in treatment effects[8,11,12,20–23]. While pragmatic trials improve real-world application of results, other barriers to interventional RCTs may remain, including ethical concerns also present a significant challenges[24,25]: for example, the use of placebos and certain treatments for older adults and children has faced criticism due to ethical considerations[26–30]. It is even more challenging to use RCTs to examine the dynamic treatment effects accounting for the time-varying nature of blood pressure[9,31,32], evaluate lifelong management[8], and understand the long-term treatment effects[8] of a hypertension interventions.

Hence, large-scale, real-world, observational data (RWD) provides a promising, alternative avenue for estimating causal treatment effects within a more general population, at much lower costs, for longer term[24,25]. The rapid growth in the use of the internet, social media, digital health technologies such as biosensors, mobile and wearable devices, as well as claims and billing activities, disease registries, and electronic health records (EHRs), together with increased capacity in data storage and computation, have led to the accumulation of large amounts of digital RWD. However, as a result of lack of rigor in the non-research-specific data collection process, estimating CTE from observational RWD is not straightforward and often leads to various sources of bias, including but not limited to: selection bias, immortal time bias, measurement bias, confounding bias (omitted confounders, unobserved confounders, time-varying confounding), and reverse causality.[25,33–36]

In response to these challenges, Target Trial Emulation (TTE) has emerged as a promising framework for CTE estimation using observational data. Following the “potential outcome” framework[37,38], TTE attempts to mimic RCTs by sampling the observational data in a deliberate fashion that closely follows RCT protocols. Although it cannot fully eliminate all biases (such as unmeasured confounders), TTE offers systematic approach to reduces biases related to erroneous study designs including selection and immortal time bias[39–41], making it especially

valuable in hypertension research. Despite the rapid increasing of TTE in medical literature in recent years, its adoption into hypertension research remains limited compared to fields like cancer or other cardiovascular research[42]. For those that claiming to use TTE may not necessarily apply the framework correctly.

Our scoping review surveys all the existing literature on applications of the TTE in hypertension research to answer the primary question: "how has TTE been applied in hypertension research?", which we further break down into: a) what types of questions have been addressed using TTE in hypertension research (e.g., comparative effectiveness of different treatments); b) what types of study designs have been effectively emulated; c) what types of biases were identified using TTE and how they were addressed (e.g., selection bias, censoring bias, confounding bias); d) whether and how studies examined heterogeneous treatment effects (HTE); e) how well the study follow the TTE framework and where the deviations occurred; f) what types of statistical or machine learning methods were applied for causal effect estimation. Based on our findings, we will offer methodological recommendations and discuss how TTE can address critical gaps in hypertension research. In addition, we hope that this review will encourage researchers to appropriately adopt the TTE framework and raise awareness of new opportunities and relevant datasets for hypertension research.

2. Methods

The protocol of this scoping review was registered in Open Science Framework ()[43]. We followed the JBI guidance[44] to conduct our scoping review and used Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) checklist to ensure the rigor of this study and methodological transparency [45] (see Supplement Appendix A for the full protocol).

2.1. Eligibility Criteria, Search strategy, and Screening

We searched PubMed, Google Scholar, Web of Science databases from January 2015 to November 18, 2024. We used multiple synonymic words or phrases representing the concept "target trial emulation" and "hypertension" as key search terms (see Supplement Appendix B). All retrieved papers were exported to COVIDENCE review management software[46]. Duplicates removing and screening were aided by COVIDENCE. After removing duplicates, three independent reviewers manually screened (A.H., H. Z., and X.S.). the titles and abstracts based on a consensus set of inclusion criteria: a) article type should be original research published in a scientific peer-reviewed journals; b) study designs should follow TTE framework at least to some extent if not entirely; c) written in English; d) the primary objective of the study should be related to hypertension and blood pressure control. Disagreements were addressed and resolved by having a discussion and majority voting during the review process. Finally, all remaining articles satisfying the inclusion criteria were fully reviewed and analyzed.

2.2. Data extraction

We extracted the following information from each study: (1) Eligibility criteria and data source, (2) Treatment strategies and assignment, (3) Outcomes, (4) Bias sources, (5) Causal contrast strategy, (6) Analysis plan and statistical methods, and (7) Limitations. The data were

independently extracted by the three reviewers (A.H., H. Z., and X.S.) and discrepancies resolved through consensus. The main idea of this extraction categorization is based on the target trial emulation design components proposed by Hernán and Robins (2016), which include eligibility criteria, treatment strategy, assignment procedure, follow-up, primary outcome definition, the causal contrast of interest, and a statistical analysis plan. Each study's design was assessed against these components. Additionally, we incorporated specific questions and categories to focus on different sources of bias. Supplemental Appendix C provides a detailed overview of the questions used to evaluate each study.

3. Results

3.1. Study characteristics

A total of 1,157 articles were retrieved from the three selected databases, with 744 duplicates removed. After screening, 14 articles met the inclusion criteria and were included in this review (see Figure 1). Of the selected studies, most were conducted in the USA (n = 9), with others from Sweden (n = 2), the Netherlands (n = 1), and the UK (n = 2), all published between 2021 and 2024.

The data sources in the USA were Veterans Health Administration (VHA), Medicare, Health and Retirement Study (HRS), Multi-Ethnic Study of Atherosclerosis (MESA), Electronic Health Record (EHR), and the IBM LCED database. In the UK, the data source was Clinical Practice Research Datalink (CPRD) and CPRD Aurum (EHR), in the Sweden combination of Electronic Health Record System and National Patient Register, Swedish Mammography Cohort (SMC) and the Cohort of Swedish Men (COSM). In the Netherlands, the data was linked between the Rotterdam Study (a prospective cohort study) and Regional Institute for Outpatient Mental Health Care dataset.



Figure 1. PRISMA Flowchart

The sample size and target population varied across the studies. Seven studies included 1,000 to 100,000 subjects[47–53], five studies had between 100,000 and 200,000 subjects[32,54–57], and two studies had a sample size of more than 200,000[54,58]. Regarding the target population, five studies were conducted among veterans, three focused on adults in

midlife, three on those over 65, one on those older than 50, two on individuals over 18, and one on those between 55 and 88 years old.

3.2. Research Focus, Treatment, and Outcome

Guided by our research question, we focused on the domain of blood pressure and hypertension. Accordingly, the research questions can be categorized in two broad categories: 1) Comparative effectiveness of different hypertension treatment strategies and management approaches (7 studies) ([32,52,54,55,57,59]); and 2) short- or long-term impact of high or uncontrolled BP (7 studies) ([47–50,56,58,60]). Table 1 summarizes most important findings. We also included a study that employed the TTE framework to explore whether existing antihypertensive medications can be repurposed to treat other health conditions ([53]).

A variety of treatment strategies and management approaches have been examined, including: remote patient monitoring([57]) and educational intervention([54]) (2 studies), Intervention time point([48]) (1 study), Sustained[49,60] and adaptive[32] Blood Pressure Control (3 studies), Diet intervention ([50]) (1 study), Different class of antihypertensive drugs([56,58]) (2 study), New Medication Versus Maximizing Dose([59]) (1 study), deprescribed or continue antihypertensive therapy[52] (1 study)and Intensive antihypertensive treatment([55]) (1 study) (See Table 1). One TTE study[56] was conducted to replicate the reference RCT while also Y investigating the generalizability of the treatments of interests.

In terms of outcome, studies are focused on the areas as follows change in SBP ([47,59]) (2 studies), Dementia and Cognitive Decline Outcomes ([48,49,51]) (3 studies), Healthcare utilization outcomes ([57]). Other Diseases Risk and other events Reduction (Cardiovascular, acute kidney injury (AKI), stroke, Hospitalization, spending, falls, and etc.) Outcomes ([32,49,50,52,54–56,58])(8 studies). Studies had different measurement approaches for outcome assessment inducing continuous, ordinal, binary, and time-to-event.

3.3. Reference RCT Type

It is noteworthy that four studies emulated a single arm RCT ([48,48,54,58]), while the remaining studies mimicked multiple-arm RCTs. In addition, one study emulated clustered RCT ([57]), where groups (or clusters) rather than individuals are randomized; another mimicked an adaptive RCT ([32]), a type that allows modifications to the trial procedures, and the remaining studies emulated a standard RCT.

3.4. Treatment Effect Estimation

Regarding causal contrast of interest, seven studies employed intention to treat (ITT)([47,51,53,54,56,57,59]), four studies used per protocol (PP)([32,49,50,58]), and two study utilized both methods ([48]), and one study did not mention ([55])(Table 1). Mean Difference, as effect size measure, was used to quantify the causal contrast of interest in two studies ([47,57,59]), Risk ratio(RR) was used in three studies([30,31,36]), three studies used hazard ratio(HR) as effect size([32,52,54,56,58]), one study employed odds ratio([55]), and one study reported both HR and RR([53]), one employed both risk difference and risk ratio([50]), one used both percentage and mean differences([59])..

3.5. Design-Based Biases

3.5.1. Sample and Immortal Time Biases

All final selected studies followed the TTE framework except one study did not include full implementation details on all the emulation and analytical steps ([59]). All studies tried to address immortal time bias by carefully defining baseline and inclusion criteria.

3.5.2. Follow-up and related Biases

The studies covered a wide range of follow-up periods, depending on the research question, from less than 30 days ([58]) to 22 years ([50]). As mentioned earlier, decisions about the approach to loss to follow-up is a common challenge, particularly when blood pressure is the outcome, due to the lack of measurements for a considerable number of patients. Studies that followed a per-protocol (PP) analysis naturally drop or censor patients who did not have blood pressure measurements at the follow-up date. However, one study employed the g-formula to handle missing data and avoid bias, rather than simply excluding those cases ([50]).

Loss to follow up bias in TTE can be approached using several methods[61–64]. One study employed stabilized inverse probability of treatment weighting (IPTW) to address biases related to loss to follow-up ([53]); one study employed time-varying stabilized inverse probability of censoring weights (IPCW) ([48,52]); two studies used IPW ([32,59]); and one study applied parametric g-formula adjusted for loss to follow-up ([50]). Eight studies did not address loss to follow-up (simply censored) or explicitly did not mention it ([47,49,51,54,55,57,58]). However, the study ([57]) that emulated a clustered randomized controlled trial (RCT) accounted for some loss to follow-up through censoring, implicitly assuming that censoring is non-informative[62], which may reduce the relevance of bias associated with this issue. Ideally, though, bias from loss to follow-up should be addressed directly[62] (See Table 1).

Specifically, regarding the loss to follow up due to lack of BP measurement before the end of the follow-up period, one study excluded patients without follow-up blood pressure measurements were from the analysis ([47]), by emphasizing independence from the outcome and using complete case analysis. Another study calculated the mean within 3 to 12 months, and if they could not find any data during these months, they addressed this loss by IPW ([59]).

3.5.3. Confounding Biases

In addressing confounding and emulating certain aspects of random assignment, various statistical methods were employed across the studies. Seven number of studies used IPW([32,47,48,52,53,56,59]), while three studies employed the g-formula method ([49–51]). Two papers utilized regression techniques ([48,57]), one paper used propensity score overlap weighting ([55]), and one paper applied propensity score matching ([58]).

To address time-varying confounders, two studies employed regression methods ([56,57]), three studies used g-formula ([49–51]), two studies applied stabilized inverse probability of treatment weighting (IPTW)([32,52]). Four studies did not account for time-varying treatment and confounders ([47,48,53,55]), one study also did not consider the time varying issue due to short horizon (30 days) over which study outcomes were assessed ([58]). One study used a serial cohort

design, including participants multiple times over the study period, which helped account for any time trends that might influence results ([54]) (See Table 1).

Regarding statistical methods to analyze outcomes, studies used one or a combination of different methods. Four studies used Cox regression model ([32,53,54,56,58]) and four studies applied logistic regression ([32,53,57,59]). Other methods included pooled logistics regression ([49,52]), weighted linear mixed-effects models ([47]), ordinary least squares regression([57]), and overlap-weighted logistic regression([55]) (See Table 1).

3.6. Heterogeneous treatment effect

In the medical field, heterogeneity of treatment effects (HTE) could be defined as the non-random variation in the direction or size of a treatment's effect, across levels of a covariate against a clinical outcome, as measured by clinical outcomes[65,66]. To address HTE in clinical trials, traditional approaches involve subgroup analyses, theory-based approach[67], either pre-planned or post hoc. In contrast, a conventional data driven approach is to split the sample based on stratifying variables (e.g., age, sex, race) and test for statistical significance in the interaction between the treatment and these variables[23,68,69]. While subgroup analyses can be useful, they can suffer from several issues and challenges. For example, each patient has many characteristics, meaning they can be part of countless potential subgroups[70] . Additional challenges include multiple comparisons (increasing type I error) and statistical power for HTE detection (type II error)[68,70]. Recently, other sophisticated model based, and data-driven approaches have developed to estimate HTE ranging from parametric, non-parametric and semi-parametric models [23,67,69,71–75].

Seven studies employed simple subgroup (pre-specified) analysis as part of their sensitivity analysis rather than focusing separately on HTE estimates ([49–52,55–57]). One study found the results consistent across the subgroups or little heterogeneity for primary outcome ([52,55,56]). In contrast, three studies found that heterogeneity across the prespecified subgroups ([50,51,58]). Six studies did not investigate the HTE ([32,47,48,53,54,59]) (See Table 1).

3.7. Study Acknowledged Limitations

We cover only the limitations mentioned by the authors; however, we addressed some limitations in the bias section of the current review (Section 3.5). In addition, some limitations specifically related to the research questions of the papers are not discussed here.

Unmeasured confounders and residual confounding were mentioned as limitations eleven times ([32,47–50,52–54,56,58,59]). Quality of data and measurement error were mentioned nine times as one of the limitations([32,47–49,51,52,56,57,59]), limited generalizability was noted eight times([51,52,54–59]), lack of blood pressure data([47,49,52,56,57]) was identified five times, time varying treatment and confounders appeared in twice([47,53]), detecting heterogeneity([47,48,51,58]) appeared four times. Although unobserved confounders is always a concern in observational studies, three studies tried to directly address this issue ([52,55,59]).

Table 1 – Summary of Extracted Information

Auth, Year	Research Question	Data Source/ year range	Treatment Strategies	Primary Outcome(s)	Causal Contrast	Bias Addressed	Method to Addressing Biases	HTE
Tang et al., 2023	Remote patient monitoring (RPM) effect on Care Outcomes	Medicare claims/ 2019-2022/Cohort Size: 114,997	Remote Patient Monitoring (RPM)	Healthcare Utilization	ITT	Time-varying Confounders	Linear Mixed-Effects Model	Subgroup and interaction analysis
						Immortal Time Bias	By design	
						Confounding Bias	Matching	
						Selection Bias	Cardinality matching	
						Selection Bias due to Loss to Follow-up	Not mentioned	
						Residual Confounding	Negative control	
Wang et al., 2023	Trajectory of blood pressure after initiating anti-CGRP treatment of migraine	Veterans' Health Administration, EHR data/2018-2023/ Cohort Size: 69589	anti-CGRP	BP trajectory, BP Changes	ITT	Time-varying Confounders	Not addressed	Subgroup analysis
						Immortal Time Bias	By design	
						Confounding Bias	IPW weighting	
						Selection Bias	IPW weighting	
						Selection Bias due to Loss to Follow-up	Not explicitly mentioned	
						Residual Confounding	Adjustment via covariates in models	
Wei et al., 2023	Effect of initiating antihypertensive medication in midlife on dementia	Health and Retirement Study (HRS)/ 1996 – 2018/ Cohort Size: 2,375	antihypertensive medication	Incident dementia	ITT & Per-protocol	Time-varying Confounders	IPCW and IPTW	Not mentioned
						Immortal Time Bias	By design (setting time zero properly)	
						Confounding Bias	IPTW	
						Selection Bias	IPTW and IPCW	
						Selection Bias due to Loss to Follow-up	IPCW	
						Residual Confounding	Not mentioned	
Rojas-Saunero et al., 2021	Effects of sustained BP reduction and smoking cessation	Rotterdam Study/1990-2005/ Cohort Size: 4930	Sustained BP reduction and smoking cessation vs. no intervention	Incident stroke, dementia	not mentioned	Time-varying Confounders	Parametric g-formula	Subgroup analysis
						Immortal Time Bias	Avoided by study design	
						Confounding Bias	Parametric g-formula	
						Selection Bias	Not mentioned, but p g-formula adjust for some bias	
						Selection Bias due to Loss to Follow-up	Not mentioned	
						Residual Confounding	Not mentioned	
Shahn et al., 2022	Repurposing effects of antihypertensive medications	Linked claims and EHR data (IBM LCED)/2021-2022/ Cohort Size: 12555	Five antihypertensive classes	Multiple (262 outcomes)	ITT	Time-varying Confounders	IPW	Subgroup and interaction analysis
						Immortal Time Bias	Avoided by study design	
						Confounding Bias	IPW	
						Selection Bias	Not mentioned, but IPW can adjust for some selection	
						Selection Bias due to Loss to Follow-up	Addressed using IPW for censoring	
						Residual Confounding	Not mentioned	
Aubert et al., 2021	Adding a new medication vs. maximizing dose for HTN treatment	Veterans' Health Administration (VHA)/2011-2013/ Cohort Size: 178562	Adding a new medication vs. increasing existing dose	BP sustainability, follow-up SBP	ITT	Time-varying Confounders	IPW	Not mentioned
						Immortal Time Bias	By design	
						Confounding Bias	IPW	
						Selection Bias	Not mentioned	
						Selection Bias due to Loss to Follow-up	Addressed using IPW for censoring	
						Residual Confounding	Sensitivity analysis (E-values)	
Brunström et al., 2022	Effect of education and feedback on HT management with risk for stroke and CVD	Swedish Stroke Prevention Study, EHR, and National Registers/2000-	Education and feedback to physicians on HT management	First-ever stroke	ITT	Time-varying Confounders	Dummy variables for time and robust variance estimators	Not mentioned
						Immortal Time Bias	Avoided by study design	
						Confounding Bias	Adjusted Cox proportional hazards model	
						Selection Bias	Not directly addressed	
						Selection Bias due to Loss to Follow-up	Not mentioned	

		2011/ Cohort Size:253289				Residual Confounding	Not mentioned	
Jiao et al., 2023	Effectiveness of different blood pressure control strategies for cardiovascular event prevention	Clinical Practice Research Datalink (CPRD) Gold, UK/ 1998-2018/ Cohort Size: 103,708	(1) Intensive, (2) Standard, (3) Conservative	MACE: Nonfatal MI, Nonfatal Stroke, ...	PP	Time-varying Confounders	IPTW	Subgroup analysis
						Immortal Time Bias	Not mentioned	
						Confounding Bias	IPTW	
						Selection Bias	IPTW for deviations from assigned treatment strategy	
						Selection Bias due to Loss to Follow-up	IPCW	
						Residual Confounding	Sensitivity analysis (adjustment in outcomes model)	
Anderson et al., 2023	Effectiveness of intensive inpatient BP treatment on clinical outcomes in older adults	VHA / 2015-2017/ Cohort Size: 114,367	Intensive BP treatment vs. non-intensive BP treatment	Composite of inpatient mortality, ICU transfer, ...	Not mentioned	Time-varying Confounders	Not explicitly addressed	Subgroup analysis
						Immortal Time Bias	Not mentioned	
						Confounding Bias	PSOW for confounding by indication	
						Selection Bias	PSOW for treatment assignment differences	
						Selection Bias due to Loss to Follow-up	Not mentioned	
						Residual Confounding	Sensitivity analysis (E-values)	
Dave et al., 2024	Is initiating antihypertensive medication associated with increased fracture risk?	Veterans Affairs National Healthcare System, 2008-2018/ Cohort Size: 623159	antihypertensive medication vs. no initiation	Fractures within 30 and 90 days	PP	Time-varying Confounders	No, too short study period	Subgroup analysis
						Immortal Time Bias	By design. Not explicitly mentioned.	
						Confounding Bias	Adjusted using PS weighting and IPW	
						Selection Bias	PS weighting to balance covariates	
						Selection Bias due to Loss to Follow-up	Censoring due to loss to follow-up	
						Residual Confounding	Assumed no unmeasured confounding.	
Ibsen et al., 2023	Effect of sustained adherence to the DASH diet on heart failure risk	Swedish Mammography Cohort, Cohort of Swedish Men/1997-2009/ Cohort Size: 66177	Population-adapted DASH diet VS no intervention	22-year risk of heart failure	PP	Time-varying Confounders	Parametric g-formula	Subgroup analysis
						Immortal Time Bias	By design. Not explicitly mentioned.	
						Confounding Bias	Parametric g-formula	
						Selection Bias	Parametric g-formula and IPW	
						Selection Bias due to Loss to Follow-up	Parametric g-formula adjusted for loss to follow-up	
						Residual Confounding	Negative control (external causes of death)	
Rojas-Saunero et al., 2024	Effect of sustained bp-lowering interventions on dementia incidence and racial disparities	Multi-Ethnic Study of Atherosclerosis /2000-2018/ Cohort Size: 16260	Maintain SBP below 120 or 140 vs. no intervention	19-year risk of dementia	Not mentioned	Time-varying Confounders	Parametric g-formula	Subgroup analysis
						Immortal Time Bias	By design. Not explicitly mentioned.	
						Confounding Bias	P g-formula (baseline and time-varying confounders)	
						Selection Bias	P g-formula (baseline and time-varying confounders)	
						Selection Bias due to Loss to Follow-up	Censoring due to loss to follow-up	
						Residual Confounding	Not explicitly addressed	
Baptiste et al., 2024	Cardiorenal effects of ACE inhibitors vs. ARBs among underrepresented groups	UK Clinical Practice Research Datalink/2001-2019/ Cohort Size: 137,155	ARB vs. ACE inhibitors	Composite: cardiovascular death, MI, ...	ITT, On-Treatment	Time-varying Confounders	Not explicitly addressed	Subgroup analysis
						Immortal Time Bias	By design. Not explicitly mentioned	
						Confounding Bias	Adjusted by propensity-score weighting and IPW	
						Selection Bias	PS weighting to balance covariates	
						Selection Bias due to Loss to Follow-up	Sensitivity analysis: Reanalyzing and excluding	
						Residual Confounding	Assumed no unmeasured confounding.	
Odden et al., 2024	Effect of antihypertensive deprescribing on cardiovascular events	VA (EHR) from Community Living Centers (CLC)/2006-2019/ Cohort Size: 13096	Deprescribing vs continued therapy	Hospitalization for MI or stroke	ITT, PP	Time-varying Confounders	IPTW, IPCW	Subgroup analysis
						Immortal Time Bias	By design	
						Confounding Bias	IPTW	
						Selection Bias	IPW to balance covariates	
						Selection Bias due to Loss to Follow-up	IPCW and sensitivity analysis	
						Residual Confounding	Negative control outcome (urinary tract infection)	

4. Discussion

Limited context of use. Our review indicates that TTE approaches have garnered growing interest in hypertension research, particularly since 2021, yet their application in this area remains less prevalent and diverse compared to other fields[42,76]. First, despite the well-recognized strength of real-world observational longitudinal data, there are still very few studies that attempted to comprehensively evaluate the long-term neurological, cardiac, and renal impacts of uncontrolled blood pressure, or the long-term effectiveness and safety of antihypertensive drugs and other management strategies (e.g. remote monitoring, smoking cessation). Second, as a result of adherence challenges and dynamic nature of the hypertension, dynamic treatment regimens (DTRs) [77,78]is another potential use context to evaluate adaptive management approaches (including timing of treatments). RCT designs (such as sequential multiple assignment randomized trials (SMARTs) and different adaptive designs, that have been developed to address DTRs) are resource-intensive, require complex design and implementation, and carry a potential for dropouts and non-compliance. However, we found only one paper addressing an adaptive strategy[32].

Third,,…..

Future work is needed to further broaden the applications of TTE approaches in hypertension research by investigating various adaptive management strategies that can better inform clinical practice for improving long-term outcomes.

Limited focus on heterogeneous treatment effects. HTE is particularly relevant in blood pressure research as there is substantial variability in patients' responses to medications (or other interventions) as well as in the short-term or long-term effects of uncontrolled blood pressure. While most RCTs can only focus on average treatment effects, TTE provides a unique opportunity to extensively evaluate heterogeneous treatment effects (HTE). Most of the selected TTE performed HTE analyses on a few pre-defined subgroups (e.g., based on age, sex, baseline BP, medication use). However, there remain opportunities to discover true high-risk and high-benefit subgroups through comprehensively leveraging all possible information (often time high-dimensional data) available in the real-world data sources. Future work is needed to explore more advanced methods (such as causal random forest) that will generate HTE-driven subgroups within the TTE framework to enhance our understanding and management of hypertension and the impact of blood pressure across diverse subgroups.

Limited focus on guideline-specific emulations. In 2017, American College of Cardiology (ACC) and American Heart Association (AHA)[7] developed new guidelines for prevention, detection, and management of high blood pressure in adults, highlighting the following major shifts: 1) more proactive and intensive management approach (e.g., targeting BP goals at 130/80 , initiating antihypertensives ; restarting antihypertensives for secondary stroke prevention); 2) treatment individualization; 3) recognition of nonpharmacological strategies; 4) advocating for remote monitoring and multidisciplinary care. ACC/AHA together with European Society of Hypertension (ESH)[79] also identified the following research gaps: optimal and safe BP thresholds and targets in old and frail patients, optimal SBP and DBP level at different time points in life, choice of first-line antihypertensive agents, ambulatory or home BP measures

across ethnicities, benefit of lifetime low BP, treatment of hypertension during pregnancy and related risks. Despite the significance of these issues, we found no studies that specifically addressed these gaps. Future work is needed to leverage TTE to provide timely evidence on the effectiveness of the guideline changes and address these well-recognized research gaps.

Lack of replication studies. There is a lack of replication studies to validate the effectiveness of TTE by directly comparing within the hypertensive research domain. Only 1 reviewed study attempted to replicate the ON-TARGET trial but included limited discussion on comparisons between the trial results and TTE results[56]. One such effort is the RCT-DUPLICATE initiative (Randomized, Controlled Trials Duplicated Using Prospective Longitudinal Insurance Claims: Applying Techniques of Epidemiology) co-launched by FDA and NIH in 2017, which, however, did not strictly follow the TTE framework[80]. Future work is needed to conduct robust replication studies that inform the reliability and limitation of TTE methodologies.

Lack of comprehensive approach on quantifying and mitigating biases. One of the biggest challenges in applying the TTE framework is the control of biases and estimation of their impact. All selected studies recognized multiple sources of bias (e.g., loss-to-follow-up bias, time-varying confounders, unmeasured confounding bias, measurement error, etc.), but only a subset of the studies primarily examined the unmeasured confounding bias via negative controls or E-value. Future work is needed to develop a robust framework to consistently identify and quantify biases that can be introduced at each TTE step, which can help with proper interpretation and use of the TTE results.

Potential of integrating causal machine learning methods. All the reviewed articles used parametric statistical models for treatment effect estimation. While development of causal machine learning methods(e.g., causal forests, counterfactual modeling) has enhanced the causal inference and predictive inference[81,82], it) remain underutilized in detecting treatment heterogeneity in BP control contexts. None of the studies used any artificial intelligence (AI) and machine learning (ML) method in any steps of their study. Future work is needed to explore the wider adoption of advanced ML techniques to improve causal contrasting and counterfactual modeling.

Limitations. The **current** scoping literature review is subject to a few limitations. First, we used several related keywords; however, since the TTE framework is rather new and still under development, researchers may use different terms to refer to TTE, leading to potential misses of relevant studies. Second, we are fully aware of the potential for publication bias, where studies with positive results are more likely to be published and thus selected in this review. Third, the subjective nature of study selection and data extraction between two reviewers may still introduce bias, particularly when disagreements arise that cannot be resolved, necessitating a judgment call; to help mitigate this bias, we used three reviewers.

5. Conclusion

This review emphasizes that Target Trial Emulation (TTE) presents a promising framework for advancing hypertension research by utilizing large-scale, real-world observational data, particularly in situations where traditional randomized controlled trials (RCTs) encounter

limitations and limited generalizability. While the applications of TTE in hypertension research is still in its early stages, current studies demonstrate its significant potential to complement and RCT studies in addressing key challenges such as heterogenous treatment effect, long-term outcome, and dynamic treatment strategies. The paucity of available studies revealed in this scoping review emphasizes the need for more TTE investigations in this area, with the potential to help clinicians and patients improve hypertension management and outcomes.

References

1. Zhou B, Perel P, Mensah GA, Ezzati M. Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension. *Nat Rev Cardiol*. 2021;18(11):785-802. doi:10.1038/s41569-021-00559-8

2. Fuchs FD, Whelton PK. High Blood Pressure and Cardiovascular Disease. *Hypertension*. 2020;75(2):285-292. doi:10.1161/HYPERTENSIONAHA.119.14240

3. Oparil S, Acelajado MC, Bakris GL, et al. Hypertension. *Nat Rev Dis Primer*. 2018;4(1):18014. doi:10.1038/nrdp.2018.14

4. Unger T, Borghi C, Charchar F, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. *Hypertension*. 2020;75(6):1334-1357. doi:10.1161/HYPERTENSIONAHA.120.15026

5. Parati G, Lombardi C, Pengo M, Bilo G, Ochoa JE. Current challenges for hypertension management: From better hypertension diagnosis to improved patients' adherence and blood pressure control. *Int J Cardiol*. 2021;331:262-269. doi:10.1016/j.ijcard.2021.01.070

6. Zhou B, Carrillo-Larco RM, Danaei G, et al. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. *The Lancet*. 2021;398(10304):957-980. doi:10.1016/S0140-6736(21)01330-1

7. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Hypertension*. Published online June 2018. doi:10.1161/HYP.0000000000000065

8. Mancia G, Kreutz R, Brunström M, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of

Hypertension (ISH) and the European Renal Association (ERA). *J Hypertens*. 2023;41(12):1874-2071. doi:10.1097/HJH.0000000000003480

9. Dzau VJ, Balatbat CA. Future of Hypertension. *Hypertension*. 2019;74(3):450-457. doi:10.1161/HYPERTENSIONAHA.119.13437

10. Lüscher TF. Unanswered questions in hypertension: prematurity and long-term trajectories, masked and white coat hypertension. *Eur Heart J*. 2020;41(16):1527-1530. doi:10.1093/eurheartj/ehaa275

11. Suchard MA, Schuemie MJ, Krumholz HM, et al. Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. *The Lancet*. 2019;394(10211):1816-1826. doi:10.1016/S0140-6736(19)32317-7

12. Ojji DB, Mayosi B, Francis V, et al. Comparison of Dual Therapies for Lowering Blood Pressure in Black Africans. *N Engl J Med*. 2019;380(25):2429-2439. doi:10.1056/NEJMoa1901113

13. Del Pinto R, Ferri C. Long-term BP variability: open questions in clinical practice. *Int J Cardiol Hypertens*. 2020;7:100064. doi:10.1016/j.ijchy.2020.100064

14. Sebo P, Pechère-Bertschi A, Herrmann FR, Haller DM, Bovier P. Blood pressure measurements are unreliable to diagnose hypertension in primary care. *J Hypertens*. 2014;32(3):509. doi:10.1097/HJH.0000000000000058

15. Kallioinen N, Hill A, Horswill MS, Ward HE, Watson MO. Sources of inaccuracy in the measurement of adult patients' resting blood pressure in clinical settings: a systematic review. *J Hypertens*. 2017;35(3):421. doi:10.1097/HJH.0000000000001197

16. Sakhuja S, Jaeger BC, Akinyelure OP, et al. Potential impact of systematic and random errors in blood pressure measurement on the prevalence of high office blood pressure in the United States. *J Clin Hypertens*. 2022;24(3):263. doi:10.1111/jch.14418

17. Shadish WR, Cook TD, Campbell DT. *Experimental and Quasi-Experimental Designs for Generalized Causal Inference*. Houghton Mifflin; 2001.

18. Athey S, Imbens GW. The Econometrics of Randomized Experiments. In: *Handbook of Economic Field Experiments*. Vol 1. Elsevier; 2017:73-140. doi:10.1016/bs.hefe.2016.10.003

19. Deaton A, Cartwright N. Understanding and misunderstanding randomized controlled trials. *Soc Sci Med*. 2018;210:2-21. doi:10.1016/j.socscimed.2017.12.005

20. Wu Y, Bai J, Zhang M, et al. Heterogeneity of Treatment Effects for Intensive Blood Pressure Therapy by Individual Components of FRS: An Unsupervised Data-Driven

Subgroup Analysis in SPRINT and ACCORD. *Front Cardiovasc Med*. 2022;9:778756. doi:10.3389/fcvm.2022.778756

21. Basu S, Sussman JB, Hayward RA. Detecting Heterogeneous Treatment Effects to Guide Personalized Blood Pressure Treatment: A Modeling Study of Randomized Clinical Trials. *Ann Intern Med*. 2017;166(5):354. doi:10.7326/M16-1756

22. Kämpfen F, Mosca I. Heterogeneous effects of blood pressure screening. *Econ Lett*. 2024;242:111845. doi:10.1016/j.econlet.2024.111845

23. Inoue K, Athey S, Baicker K, Tsugawa Y. Heterogeneous effects of Medicaid coverage on cardiovascular risk factors: secondary analysis of randomized controlled trial. *BMJ*. Published online September 23, 2024:e079377. doi:10.1136/bmj-2024-079377

24. Corrao G, Mancia G. Research strategies in treatment of hypertension: value of retrospective real-life data. *Eur Heart J*. 2022;43(35):3312-3322. doi:10.1093/eurheartj/ehab899

25. Hernán MA, Robins JM. Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available: Table 1. *Am J Epidemiol*. 2016;183(8):758-764. doi:10.1093/aje/kwv254

26. Flynn JT. Ethics of Placebo Use in Pediatric Clinical Trials. *Hypertension*. 2003;42(5):865-869. doi:10.1161/01.HYP.0000095616.91352.2E

27. Halpern SD, Karlawish JHT. Placebo-Controlled Trials Are Unethical in Clinical Hypertension Research. *Arch Intern Med*. 2000;160(20):3167-3168.

28. Kim SYH, Miller FG. Ethical complexities in standard of care randomized trials: A case study of morning versus nighttime dosing of blood pressure drugs. *Clin Trials Lond Engl*. 2015;12(6):557-563. doi:10.1177/1740774515607213

29. Pfeffer MA, McMurray JJV. Lessons in Uncertainty and Humility — Clinical Trials Involving Hypertension. *N Engl J Med*. 2016;375(18):1756-1766. doi:10.1056/NEJMra1510067

30. Shayo E, Hout MCV, Birungi J, et al. Ethical issues in intervention studies on the prevention and management of diabetes and hypertension in sub-Saharan Africa. *BMJ Glob Health*. 2020;5(7):e002193. doi:10.1136/bmjgh-2019-002193

31. Lavori PW, Dawson R. Introduction to dynamic treatment strategies and sequential multiple assignment randomization. *Clin Trials*. 2014;11(4):393-399. doi:10.1177/1740774514527651

32. Jiao T, Platt RW, Douros A, Filion KB. Use of a Statistical Adaptive Treatment Strategy Approach for Emulating Randomized Controlled Trials Using Observational Data: The Example of Blood-Pressure Control Strategies for the Prevention of Cardiovascular Events Among Individuals With Hypertension at High Cardiovascular Risk. *Am J Epidemiol*. 2023;192(9):1576-1591. doi:10.1093/aje/kwad091

33. Gueyffier F, Cucherat M. The limitations of observation studies for decision making regarding drugs efficacy and safety. *Therapies*. 2019;74(2):181-185. doi:10.1016/j.therap.2018.11.001

34. Boyko EJ. Observational research — opportunities and limitations. *J Diabetes Complications*. 2013;27(6):642-648. doi:10.1016/j.jdiacomp.2013.07.007

35. Grimes DA, Schulz KF. Bias and causal associations in observational research. *The Lancet*. 2002;359(9302):248-252. doi:10.1016/S0140-6736(02)07451-2

36. Hammerton G, Munafò MR. Causal inference with observational data: the need for triangulation of evidence. *Psychol Med*. 2021;51(4):563-578. doi:10.1017/S0033291720005127

37. NEYMAN J. On the application of probability theory to agricultural experiments. Essay on principles. *Ann Agric Sci*. Published online 1923:1-51.

38. Rubin DB. Estimating causal effects of treatments in randomized and nonrandomized studies. *J Educ Psychol*. 1974;66(5):688-701. doi:10.1037/h0037350

39. Hernán MA, Wang W, Leaf DE. Target Trial Emulation: A Framework for Causal Inference From Observational Data. *JAMA*. 2022;328(24):2446. doi:10.1001/jama.2022.21383

40. Fu EL. Target Trial Emulation to Improve Causal Inference from Observational Data: What, Why, and How? *J Am Soc Nephrol*. 2023;34(8):1305-1314. doi:10.1681/ASN.0000000000000152

41. Hernán MA. Methods of Public Health Research — Strengthening Causal Inference from Observational Data. *N Engl J Med*. 2021;385(15):1345-1348. doi:10.1056/NEJMp2113319

42. Zuo H, Yu L, Campbell SM, Yamamoto SS, Yuan Y. The implementation of target trial emulation for causal inference: a scoping review. *J Clin Epidemiol*. 2023;162:29-37. doi:10.1016/j.jclinepi.2023.08.003

43. Habibdoust A, Song X. Target Trial Emulation in Blood Pressure and Hypertension: A Scoping Review of Practices, Limitations, and Future Implications. Published online September 16, 2024. Accessed March 14, 2025. https://osf.io/tusfe/

44. Peters MDJ, Marnie C, Tricco AC, et al. Updated methodological guidance for the conduct of scoping reviews. *JBI Evid Synth*. 2020;18(10):2119-2126. doi:10.11124/JBIES-20-00167

45. Tricco AC, Lillie E, Zarin W, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. *Ann Intern Med*. 2018;169(7):467-473. doi:10.7326/M18-0850

46. Covidence systematic review software, Veritas Health Innovation, Melbourne, Australia. www.covidence.org

47. Wang K, Fenton BT, Dao VX, et al. Trajectory of blood pressure after initiating anti-calcitonin gene-related peptide treatment of migraine: a target trial emulation from the veterans health administration. *J Headache Pain*. 2023;24(1):108. doi:10.1186/s10194-023-01640-y

48. Wei J, Xu H, Zhang D, et al. Initiation of Antihypertensive Medication from Midlife on Incident Dementia: The Health and Retirement Study. *J Alzheimers Dis*. 2023;94(4):1431-1441. doi:10.3233/JAD-230398

49. Rojas-Saunero LP, Hilal S, Murray EJ, Logan RW, Ikram MA, Swanson SA. Hypothetical blood-pressure-lowering interventions and risk of stroke and dementia. *Eur J Epidemiol*. 2021;36(1):69-79. doi:10.1007/s10654-020-00694-5

50. Ibsen DB, Chiu YH, Gémes K, Wolk A. Hypothetical 22-Year Intervention With the Dietary Approaches to Stop Hypertension and Risk of Heart Failure in a General Population. *Am J Epidemiol*. 2024;193(1):96-106. doi:10.1093/aje/kwad181

51. Rojas-Saunero LP, Hughes TM, Mayeda ER, Jimenez MP. Racial and ethnic differences in the risk of dementia diagnosis under hypothetical blood pressure–lowering interventions: The Multi-Ethnic Study of Atherosclerosis. *Alzheimers Dement*. 2024;20(8):5271-5280. doi:10.1002/alz.13894

52. Odden MC, Graham LA, Liu X, et al. Antihypertensive Deprescribing and Cardiovascular Events Among Long-Term Care Residents. *JAMA Netw Open*. 2024;7(11):e2446851. doi:10.1001/jamanetworkopen.2024.46851

53. Shahn Z, Spear P, Lu H, et al. Systematically exploring repurposing effects of antihypertensives. *Pharmacoepidemiol Drug Saf*. 2022;31(9):944-952. doi:10.1002/pds.5491

54. Brunström M, Ng N, Dahlström J, et al. Association of education and feedback on hypertension management with risk for stroke and cardiovascular disease. *Blood Press*. 2022;31(1):31-39. doi:10.1080/08037051.2022.2041393

55. Anderson TS, Herzig SJ, Jing B, et al. Clinical Outcomes of Intensive Inpatient Blood Pressure Management in Hospitalized Older Adults. *JAMA Intern Med*. 2023;183(7):715. doi:10.1001/jamainternmed.2023.1667

56. Baptiste PJ, Wong AYS, Schultze A, et al. Effectiveness and risk of ARB and ACEi among different ethnic groups in England: A reference trial (ONTARGET) emulation analysis using UK Clinical Practice Research Datalink Aurum-linked data. *PLoS Med*. 2024;21(9):e1004465. doi:10.1371/journal.pmed.1004465

57. Tang M, Nakamoto CH, Stern AD, et al. Effects of Remote Patient Monitoring Use on Care Outcomes Among Medicare Patients With Hypertension: An Observational Study. *Ann Intern Med*. 2023;176(11):1465-1475. doi:10.7326/M23-1182

58. Dave CV, Li Y, Steinman MA, et al. Antihypertensive Medication and Fracture Risk in Older Veterans Health Administration Nursing Home Residents. *JAMA Intern Med*. 2024;184(6):661. doi:10.1001/jamainternmed.2024.0507

59. Aubert CE, Sussman JB, Hofer TP, Cushman WC, Ha JK, Min L. Adding a New Medication Versus Maximizing Dose to Intensify Hypertension Treatment in Older Adults: A Retrospective Observational Study. *Ann Intern Med*. 2021;174(12):1666-1673. doi:10.7326/M21-1456

60. Abrahamowicz AA, Ebinger J, Whelton SP, Commodore-Mensah Y, Yang E. Racial and Ethnic Disparities in Hypertension: Barriers and Opportunities to Improve Blood Pressure Control. *Curr Cardiol Rep*. 2023;25(1):17-27. doi:10.1007/s11886-022-01826-x

61. Hernan MA, Robins JM. *Causal Inference: What If*. 1st edition. CRC Press; 2025.

62. Howe CJ, Cole SR, Lau B, Napravnik S, Eron JJJ. Selection Bias Due to Loss to Follow Up in Cohort Studies. *Epidemiology*. 2016;27(1):91. doi:10.1097/EDE.0000000000000409

63. Graham SM, Raboud J, McClelland RS, et al. Loss to Follow-Up as a Competing Risk in an Observational Study of HIV-1 Incidence. *PLOS ONE*. 2013;8(3):e59480. doi:10.1371/journal.pone.0059480

64. Groenwold RHH, Donders ART, Roes KCB, Harrell FE Jr, Moons KGM. Dealing With Missing Outcome Data in Randomized Trials and Observational Studies. *Am J Epidemiol*. 2012;175(3):210-217. doi:10.1093/aje/kwr302

65. Varadhan R, Seeger JD. Estimation and Reporting of Heterogeneity of Treatment Effects. In: *Developing a Protocol for Observational Comparative Effectiveness Research: A User's Guide*. Agency for Healthcare Research and Quality (US); 2013. Accessed October 10, 2024. https://www.ncbi.nlm.nih.gov/books/NBK126188/

66. Kent DM, Paulus JK, Van Klaveren D, et al. The Predictive Approaches to Treatment effect Heterogeneity (PATH) Statement. *Ann Intern Med*. 2020;172(1):35. doi:10.7326/M18-3667

67. Salditt M, Eckes T, Nestler S. A Tutorial Introduction to Heterogeneous Treatment Effect Estimation with Meta-learners. *Adm Policy Ment Health Ment Health Serv Res*. 2024;51(5):650-673. doi:10.1007/s10488-023-01303-9

68. Sormani MP, Chataway J, Kent DM, Marrie RA. Assessing heterogeneity of treatment effect in multiple sclerosis trials. *Mult Scler J*. 2023;29(9):1158-1161. doi:10.1177/13524585231189673

69. Lipkovich I, Svensson D, Ratitch B, Dmitrienko A. Overview of modern approaches for identifying and evaluating heterogeneous treatment effects from clinical data. *Clin Trials*. 2023;20(4):380-393. doi:10.1177/17407745231174544

70. Dahabreh IJ, Hayward R, Kent DM. Using group data to treat individuals: understanding heterogeneous treatment effects in the age of precision medicine and patient-centred evidence. *Int J Epidemiol*. Published online November 17, 2016:dyw125. doi:10.1093/ije/dyw125

71. Ling Y, Upadhyaya P, Chen L, Jiang X, Kim Y. Emulate randomized clinical trials using heterogeneous treatment effect estimation for personalized treatments: Methodology review and benchmark. *J Biomed Inform*. 2023;137:104256. doi:10.1016/j.jbi.2022.104256

72. N J, K K, Mc O, et al. Practical Guide to Honest Causal Forests for Identifying Heterogeneous Treatment Effects. *Am J Epidemiol*. 2023;192(7). doi:10.1093/aje/kwad043

73. Dandl S, Bender A, Hothorn T. Heterogeneous treatment effect estimation for observational data using model-based forests. *Stat Methods Med Res*. 2024;33(3):392-413. doi:10.1177/09622802231224628

74. Chernozhukov V, Chetverikov D, Demirer M, et al. Double/debiased machine learning for treatment and structural parameters. *Econom J*. 2018;21(1):C1-C68. doi:10.1111/ectj.12097

75. Hu L, Ji J, Li F. Estimating heterogeneous survival treatment effect in observational data using machine learning. *Stat Med*. 2021;40(21):4691-4713. doi:10.1002/sim.9090

76. Komura T, Watanabe M, Shioda K. Exploring the Application of Target Trial Emulation in Vaccine Evaluation: Scoping Review. *Am J Epidemiol*. Published online March 10, 2025:kwaf053. doi:10.1093/aje/kwaf053

77. Choi SE, Brandeau ML, Basu S. Dynamic treatment selection and modification for personalised blood pressure therapy using a Markov decision process model: a cost-effectiveness analysis. *BMJ Open*. 2017;7(11):e018374. doi:10.1136/bmjopen-2017-018374

78. Kidwell KM, Almirall D. Sequential, Multiple Assignment, Randomized Trial Designs. *JAMA*. 2023;329(4):336-337. doi:10.1001/jama.2022.24324

79. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. *Eur Heart J*. 2018;39(33):3021-3104. doi:10.1093/eurheartj/ehy339

80. Wang SV, Schneeweiss S, RCT-DUPLICATE Initiative. Emulation of Randomized Clinical Trials With Nonrandomized Database Analyses: Results of 32 Clinical Trials. *JAMA*. 2023;329(16):1376-1385. doi:10.1001/jama.2023.4221

81. Li S, Chu Z, eds. *Machine Learning for Causal Inference*. Springer International Publishing; 2023. doi:10.1007/978-3-031-35051-1

82. Chernozhukov V, Hansen C, Kallus N, Spindler M, Syrgkanis V. Applied Causal Inference Powered by ML and AI. *Papers*. Published online March 2024. Accessed October 11, 2024. https://ideas.repec.org//p/arx/papers/2403.02467.html